-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Monthly Archives: October 2009
Positive results for Logical Therapeutics’ LT-NS001 vs. Naproxen clinical study
Logical Therapeutics, Inc. announced positive results of a Phase I/II clinical trial evaluating the gastrointestinal (GI) safety of its investigational drug LT-NS001, the first of a new class of bio-activated prodrugs being developed for the chronic treatment of arthritic conditions.
Endocyte awarded patent for vitamin receptor binding drug delivery conjugates
Endocyte, Inc. has been awarded a patent from the United States Patent and Trademark Office covering vitamin receptor binding anti-cancer agents. The patent, entitled “Vitamin Receptor Binding Drug Delivery Conjugates” (U.S. Patent No. 7,601,332), covers novel conjugation linkages and anti-cancer agents, including Endocyte’s EC145, which is currently in development as a potential treatment for ovarian and non-small cell lung cancers.
Oncolytics® Biotech Inc. issues 33rd U.S. patent
Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) has been granted its 33rd U.S. Patent, No. 7,608,257, entitled “Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells With a Virus.” The patent claims cover methods of using reovirus in combination with currently approved chemotherapeutic agents to treat patients that are refractory to those chemotherapeutic agents alone. Read the release.
Biotech and the flu pandemic
Biotechnology researchers are working to create new vaccination options to help stop the next big pandemic before it starts. Join Dr. Targan of BIO’s BioBytes as he walks us through the current steps in vaccine production, and what biotechnology is doing to help create new vaccines in quicker timeframes to help meet the global demand (click link below for video). For those of you attending the 8th Annual BIO Investor Forum this week in San Read More >
Record soy exports expose critical flaw in land use theory
As has been pointed out multiple times on this blog, there are serious flaws in the theory of indirect land use change (ILUC) and the models used to predict it. But that’s not where the flaws end. There are also significant errors in data. As National Biodiesel Board CEO Joe Jobe said in a recent interview regarding ILUC theory: The elements that are not predictions, that are known, quantifiable data are actually wrong. Well, another piece Read More >
